Krop IE was the most productive and cited author in the holistic field, who has participated in several crucial clinical trials for T-DM1 in the treatment of HER2-positive breast cancer, such as the EMILIA (Verma et al., 2012) and TH3RESA (Krop et al., 2014) trials. Here, ERBB2 is linked to breast carcinoma.